The assistant professor of neurology at Mayo Clinic provided his thoughts on the next steps in understanding autoimmune encephalitis and the direction that research must pivot to.
Videos
The chief medical officer at Clene Nanomedicine discussed the recently presented data on CNM-Au8 from the VISIONARY-MS trial.
The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical discussed areas of multiple sclerosis research that need more attention.
The assistant professor of neurology at Mayo Clinic detailed his presentation at ACTRIMS 2021 Forum on the rising prevalence of autoimmune encephalitis.
The neurologist from Massachusetts General Hospital gave an overview of her study presented at ACTRIMS.
The global head of medical affairs-neurology at Janssen Pharmaceutical provided background on the need for real-world studies and how they can accurately portray a disease community.
Neurology News Network for the week ending February 27, 2021.
The fellow of autoimmune neurology at Massachusetts General Hospital discussed the analysis his team conducted to clarify the known associations.
The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical detailed the areas research has grown in MS and areas that still need more examination.
The global head of medical affairs-neurology at Janssen Pharmaceutical discussed 2 studies presented at the ACTRIMS Forum 2021 involving fatigue among patients with multiple sclerosis.
The director and founder of the Sleep Centers of Middle Tennessee compared the integrated care model of ISPs to the transactional model of DMEs.
The assistant professor of pediatric neurology at the Washington University in St. Louis spoke to the insights of a recent survey she and colleagues conducted.
The assistant professor of neurology at Thomas Jefferson University gave background on what other studies have observed brain implants for poststroke patients and how they differ from his work.
The director of the Montefiore Headache Center discussed how rimegepant has certain benefits over monoclonal antibodies, such as a much shorter half-life.
The director of the Massachusetts General Hospital ALS Care Center detailed the role genetic backgrounds can have on outcomes within ALS clinical trials.
The chief scientific officer of the Parkinson’s Foundation discussed the importance of screening for mood disturbances in patients with PD.
The director of the Massachusetts General Hospital ALS Care Center discussed some of the biggest challenges for patients with ALS and what should be prioritized in research.
Neurology News Network for the week ending February 20, 2021.
The founder and director of the Sleep Centers of Middle Tennessee discussed how patients that better understand the benefits of PAP therapy had better adherence to the therapy.
The director of the Schey Center for Cognitive Neuroimaging at Cleveland Clinic shared the next steps in building on previous research that links exercise with a reduced Alzheimer disease risk.
The director of the Montefiore Headache Center discussed the impact of halving headache days for patients with migraine.
A roundtable discussion featuring Scott Perry, MD, Orrin Devinsky, MD, and Tracy Salazar, PhD, details how advocacy organizations can help guide patients with epilepsy and their caregivers with a seizure action plan.
A roundtable discussion featuring Scott Perry, MD, Orrin Devinsky, MD, and Tracy Salazar, PhD, details how seizure action plans change from pediatrics to adults and the need for adjustments.
The assistant professor of neurology at Thomas Jefferson University provided perspective on how researchers have gained a better understanding of using modalities in poststroke patients.
The Evelyn F. McKnight Neurocognitive Scholar at the University of Miami Miller School of Medicine discussed observing how sleep may impact cognitive decline in different populations.
The assistant professor of pediatric neurology at Washington University in St. Louis spoke to the results of a recent survey she and colleagues conducted.
The chief scientific officer of the Parkinson’s Foundation discussed the state of mental health services for people with Parkinson disease during the COVID-19 pandemic.
The AASM board of directors' member and professor of medicine at UCLA discussed the benefits of CBT-I and its efficacy compared to pharmacological treatments.
Advertisement
Advertisement
